These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1758 related items for PubMed ID: 17559729

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients.
    Stewart DE, Wohlreich MM, Mallinckrodt CH, Watkin JG, Kornstein SG.
    J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 8. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.
    Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV.
    Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562
    [Abstract] [Full Text] [Related]

  • 9. Safety and tolerability of duloxetine at 60 mg once daily in elderly patients with major depressive disorder.
    Raskin J, Wiltse CG, Dinkel JJ, Walker DJ, Desaiah D, Katona C.
    J Clin Psychopharmacol; 2008 Feb; 28(1):32-8. PubMed ID: 18204338
    [Abstract] [Full Text] [Related]

  • 10. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J, McNamara RK, Mallinckrodt CH, Rayamajhi JN, Raskin J.
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [Abstract] [Full Text] [Related]

  • 11. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 12. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 13. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.
    Arthritis Rheum; 2004 Sep 04; 50(9):2974-84. PubMed ID: 15457467
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Sep 04; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 15. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS, Reines EH, Guiton C, Weiller E.
    Ann Pharmacother; 2007 Oct 04; 41(10):1583-92. PubMed ID: 17848424
    [Abstract] [Full Text] [Related]

  • 16. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ, Gopal M, Zheng W, Martinez JM, Robinson MJ, Marangell LB.
    Curr Med Res Opin; 2011 Oct 04; 27(10):1849-58. PubMed ID: 21838411
    [Abstract] [Full Text] [Related]

  • 17. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
    Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD.
    J Psychiatr Res; 2005 Mar 04; 39(2):161-72. PubMed ID: 15589564
    [Abstract] [Full Text] [Related]

  • 18. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct 04; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 19. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM, Hudson JI, Wang F, Wohlreich MM, Prakash A, Kajdasz DK, Chappell AS.
    Clin J Pain; 2009 Oct 04; 25(6):461-8. PubMed ID: 19542792
    [Abstract] [Full Text] [Related]

  • 20. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG, Schlaepfer TE, Andersen HF, Kilts CD.
    J Psychiatr Res; 2009 Feb 04; 43(5):568-75. PubMed ID: 18954875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 88.